Previous 10 | Next 10 |
- Precision-designed potent and selective CDK7 inhibitor with potential for improved therapeutic index - - Preclinically discovered non-invasive PD biomarker to be confirmed alongside clinical trial - Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first...
- Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development - - Parallel translational initiative to evaluate preclinically identified non-invasive PD biomarkers with potential to predict GTAEXS6...
Expanded leadership structure maintains nimble technology development across multitude of discovery and development functions Exscientia plc (Nasdaq: EXAI) announced today that it is expanding its technology management structure to accelerate application of Exscientia's innovative techn...
Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 11:20 a.m. PDT (7:20 p.m. BST). A live webcast of the fireside chat will be ...
2023-05-30 10:01:01 ET Gainers: HeartBeam ( BEAT ) +23% . Taro Pharmaceutical Industries ( TARO ) +22% . Akebia Therapeutics ( AKBA ) +19% . Corvus Pharmaceuticals ( CRVS ) +16% . Immix Biopharma ( IMMX ) +13% . Losers:...
2023-05-26 11:23:47 ET Shares of Exscientia (NASDAQ: EXAI) were up 30.3% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence . The artificial intelligence (AI)-driven precision medicine biotech stock is up more than 47% so far ...
2023-05-24 18:28:00 ET For a company operating in an area of great investor interest, even a mild quarterly earnings beat can really juice its stock price. That was the dynamic behind artificial intelligence (AI)-powered healthcare-solutions provider Exscientia 's (NASDAQ: EXAI) mor...
2023-05-24 14:15:24 ET Exscientia plc (EXAI) Q1 2023 Earnings Conference Call May 23, 2023 08:30 ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Dave Hallett - Chief Scientific Officer Ben T...
2023-05-24 07:06:29 ET Exscientia press release ( NASDAQ: EXAI ): Q1 GAAP EPS of -$0.38. Revenue of $7.1M (-17.4% Y/Y). For further details see: Exscientia GAAP EPS of -$0.38, revenue of $7.1M
Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...